Clinical Trials Browser

Phase 2 × INDUSTRY × Non-squamous Non-small-cell Lung Cancer × Clear all

NCT05849246 2024-08-20

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Phase 2 Terminated

Non-squamous Non-small-cell Lung Cancer